CRLconf 0.95

kresladi — CRL

$RCKT · ROCKET PHARMACEUTICALS, INC. · Treatment of pediatric patients with severe leukocyte adhesion deficiency-I (LAD-I) due to biallelic variants in ITGB2 without an available human leukocyte antigen-matched sibling donor for allogeneic hematopoietic stem cell transplant

Event date

Date TBD

Sponsor runway

10 mo

$144.4M liquid

Evidence

“The U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) in response to Rocket's Biologics License Application for KRESLADI™ wherein the FDA requested limited additional Chemistry Manufacturing and Controls (CMC) information to complete its review.”

Source: Press release · 2024-06-28View press release ↗

Comparable historical crls· last 5 years · same event type

No comparable historical outcomes in our database yet — backfill of past readouts arrives next ingestion cycle.

Recent insider activity· ±90 days

4 insiders · 0 buys · 7 sells

Sell

2026-05-19

Wilson Martin

General Counsel

662 @ $3.01$2K

Sell

2026-05-19

Militello John

See Remarks

384 @ $3.01$1K

Sell

2026-05-19

Shah Gaurav

CEO

2,409 @ $3.01$7K

Sell

2026-05-13

Wilson Martin

General Counsel

3,361 @ $3.61$12K

Sell

2026-05-13

Shah Gaurav

CEO

2,728 @ $3.61$10K

Sell

2026-05-13

Militello John

See Remarks

855 @ $3.61$3K

Sell

2026-05-07

Chaudhuri Sarbani

See Remarks

17,650 @ $3.84$68K

Date	Insider	Action	Shares	Price	Value
2026-05-19	Wilson MartinGeneral Counsel	Sell	662	$3.01	$2K
2026-05-19	Militello JohnSee Remarks	Sell	384	$3.01	$1K
2026-05-19	Shah GauravCEO	Sell	2,409	$3.01	$7K
2026-05-13	Wilson MartinGeneral Counsel	Sell	3,361	$3.61	$12K
2026-05-13	Shah GauravCEO	Sell	2,728	$3.61	$10K
2026-05-13	Militello JohnSee Remarks	Sell	855	$3.61	$3K
2026-05-07	Chaudhuri SarbaniSee Remarks	Sell	17,650	$3.84	$68K

← All catalysts for $RCKT